Seppi Klaus, Yekhlef Farid, Diem Anja, Luginger Wolf Elisabeth, Mueller Joerg, Tison François, Quinn Niall P, Poewe Werner, Wenning Gregor K
Department of Neurology, University Hospital, Innsbruck, Austria.
J Neurol. 2005 Jan;252(1):91-6. doi: 10.1007/s00415-005-0617-2.
Progression of parkinsonian motor impairment is usually rapid and relentless in multiple system atrophy (MSA). However, it may also be subject to considerable variation. Prospective natural history studies using validated rating scales are required to accurately determine the progression of parkinsonism in MSA.
To assess the progression of parkinsonism in patients with the Parkinson variant of MSA.
Parkinsonian motor impairment was assessed on regular therapy at two time points (mean follow-up 11.8 months, SD 1.4) using the Hoehn and Yahr scale (H&Y), the Schwab and England ADL scale (SES) and the motor examination section of the UPDRS (UPDRS-III) in 38 patients with clinically probable MSA-P.
We examined 38 patients with probable MSA-P (mean age 63.2 years, SD 7.4; mean disease duration 4.1 years, SD 3.0). The mean difference of UPDRS-III between baseline and follow-up was 10.8 (95% CI 8.6-12.9), consistent with an average annual 28.3 % increase of UPDRS-III baseline scores. Several variables were associated with faster progression of parkinsonism including low baseline global motor disability as assessed by H&Y and SES, low baseline UPDRS-III score, and short disease duration. UPDRS-III progression was unrelated to gender, age at symptom onset, and age at baseline visit.
This is the first observational study on UPDRS rates of decline in MSA. The observed 28.6% annual increase of UPDRS-III scores illustrates the rapid progression of motor impairment in MSA. Furthermore, motor progression appeared to be accelerated during the early disease stages. Our data allow sample size calculations that may be helpful for the planning of future therapeutic trials.
在多系统萎缩(MSA)中,帕金森氏运动障碍的进展通常迅速且持续。然而,其进展也可能存在相当大的差异。需要使用经过验证的评分量表进行前瞻性自然史研究,以准确确定MSA中帕金森症的进展情况。
评估MSA帕金森变异型患者帕金森症的进展情况。
使用Hoehn和Yahr量表(H&Y)、Schwab和England日常生活活动量表(SES)以及统一帕金森病评定量表运动检查部分(UPDRS-III),在两个时间点(平均随访11.8个月,标准差1.4)对38例临床可能为MSA-P的患者进行常规治疗时的帕金森氏运动障碍评估。
我们检查了38例可能为MSA-P的患者(平均年龄63.2岁,标准差7.4;平均病程4.1年,标准差3.0)。UPDRS-III在基线和随访之间的平均差异为10.8(95%可信区间8.6 - 12.9),这与UPDRS-III基线评分平均每年增加28.3%一致。几个变量与帕金森症进展较快相关,包括H&Y和SES评估的低基线整体运动残疾、低基线UPDRS-III评分以及病程短。UPDRS-III的进展与性别、症状发作年龄和基线访视年龄无关。
这是第一项关于MSA中UPDRS下降率的观察性研究。观察到的UPDRS-III评分每年28.6%的增加说明了MSA中运动障碍的快速进展。此外,运动进展在疾病早期阶段似乎加速。我们的数据可用于样本量计算,这可能有助于未来治疗试验的规划。